Sufentanil in Patients With Lower Extremity Fracture Surgery Myocardial Damage Function Study

Launched by SECOND HOSPITAL OF SHANXI MEDICAL UNIVERSITY · Feb 4, 2025

Keywords

ClinConnect Summary

This clinical trial is investigating how different doses of a pain medication called sufentanil affect heart health in patients undergoing surgery for lower limb fractures. Specifically, the researchers want to understand how these doses might protect the heart or cause damage during and after the surgery, particularly looking at certain biological markers in the body. They will also monitor any heart-related problems that could arise during the surgery and recovery.

To be eligible for this trial, participants should be between 18 and 65 years old and need surgery for a fracture in their lower limbs. However, individuals with certain heart conditions, recent heart attacks, or other serious health issues like liver or kidney failure will not be included. If you participate, you can expect to receive different doses of sufentanil during your surgery and have your heart health monitored throughout the process. This study aims to ensure safer surgical outcomes for patients with fractures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • There were 160 patients aged 18-65 years and older who needed surgery for lower extremity fracture.
• • ASA grades I to III, gender is not limited.
• Exclusion Criteria:
• • Patients with acute myocardial infarction in the last 6 months, those with a history of heart failure, and those with elevated troponin levels before injury.
• • Old fracture
• • Stroke patients
• • Liver cirrhosis, kidney failure
• • Serious systemic infections, alcoholism, drug dependence
• • Pathological fracture
• • Use of glucocorticoids in the past one month
• • Diabetic